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Abstract
Background: Deficiency of membrane G-protein coupled receptor (GPCR) kinase-5 (GRK5)
recently has been linked to early AD pathogenesis, and has been suggested to contribute to
augmented microglial activation in vitro by sensitizing relevant GPCRs. However, GRK5 deficient
mice did not show any signs of microgliosis, except for their moderate increase in axonal defects
and synaptic degenerative changes during aging. We have speculated that one possible reason for
the absence of microgliosis in these animals might be due to lack of an active inflammatory process
involving activated GPCR signaling, since GRKs only act on activated GPCRs. The objective of this
study was to determine whether the microgliosis is exaggerated in TgAPPsw (Tg2576) mice also
deficient in GRK5, in which fibrillar β-amyloid (Aβ) and an active inflammatory process involving
activated GPCR signaling are present.
Methods: Both quantitative and qualitative immunochemistry methods were used to evaluate the
microgliosis and astrogliosis in these animals. 
Results: We found that inactivation of one copy of the GRK5 gene in the TgAPPsw mice resulted
in approximately doubled extent of microgliosis, along with significantly exaggerated astrogliosis, in
both hippocampus and cortex of the aged animals. Consistent with previous observations, the
activated microglia were located primarily near or surrounding the fibrillar Aβ deposits.
Conclusion:  The results demonstrate that GRK5 deficiency in vivo significantly exaggerates
microgliosis and astrogliosis in the presence of an inflammatory initiator, such as the excess fibrillar
Aβ and the subsequent active inflammatory reactions in the TgAPPsw mice.
Background
Alzheimer's disease (AD) is a devastating neurodegenera-
tive disorder affecting a growing number among the aging
population. Although its etiology remains to be eluci-
dated, pathological evidence indicates that, in addition to
the characteristic senile plaques and neurofibrillary tan-
gles, significant brain inflammatory changes, featured
with exaggerated gliosis and increased proinflammatory
cytokines, are an important component of the pathology
[1,2].
Inflammation is a double-edged sword. For instance in
AD, an appropriate degree of inflammatory reaction may
be beneficial for clearance of aggregated proteins and/or
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degenerated cells. However, if the inflammation is overly
reactive, the secondary inflammatory neuronal damage
may become a driving force for the disease, as appears to
be the case in AD [1]. Therefore, it is important to under-
stand what factors may exaggerate the brain inflammation
in AD so that corresponding therapeutic approaches can
be developed to ameliorate such changes.
The extent of inflammatory reactions may be regulated by
a variety of factors, such as proinflammatory cytokines,
chemokines, complement systems, and others. In AD,
fibrillar β-amyloid (Aβ) has been shown to directly acti-
vate microglial cells and result in increased levels of proin-
flammatory cytokines, such as interleukin-1 beta (IL-1β)
and tumor necrosis factor-α [1-3]. In addition, it can acti-
vate the complement system to generate C3a and C5a [4].
Moreover, fibrillar Aβ accumulation is associated with
increased levels of many chemokines and chemokine
receptors, such as monocyte chemoattractant protein-1
(CCR2 ligand), macrophage inflammatory protein 1
(CCR3 ligand), interferon-inducible protein-10 (CXCR3
ligand), IL-8 (ligand for CXCXR1 and CXCR2) and CCR1/
3/5. [5-7]. Amongst the inflammatory regulators associ-
ated with AD, there is one large category that exerts their
cellular effects through heterotrimeric G-protein-coupled
receptors (GPCRs). These include all the chemokines [6]
and the anaphylatoxins C3a and C5a [8,9].
In a recent study, we showed that deficiency of membrane
GPCR kinase-5 (GRK5) occurs during early AD, and the
GRK5 deficiency contributes to augmented microglial
activation in vitro via impaired sensitization of relevant
GPCRs [10]. GRK5 is one of seven GRK family members,
whose primary function is to desensitize activated GPCRs
by phosphorylating the activated receptor to promote
uncoupling of receptor-dependent G-protein activation
and by initiating receptor internalization [11,12]. There-
fore, the lack of membrane (functional) GRK5 resulted in
prolonged signaling and enhanced microglial activation,
which well explained the phenomena that we observed in
the cultured microglial cells [10]. Moreover, we specu-
lated that the same phenomena might also take place in
vivo. However, our later study in GRK5 deficient mice
(GRK5KO), an animal model resembling the functional
GRK5 deficiency in AD, failed to show any sign of micro-
gliosis, except for moderate increase in axonal defects and
synaptic degenerative changes in these animals [13]. The
negative in vivo data appeared to be inconsistent with our
earlier in vitro data. Nonetheless, a hallmark of GRK action
is to function only after GPCRs are activated [11,12]. In
other words, whether or not an impact of GRK5 deficiency
on a particular stimulus can be revealed depends on
whether or not such a stimulus is present. We have
reported that, although the GRK5 deficiency indeed
caused a mild increase of Aβ level, no fibrillar Aβ deposits
or any significant signs of microglial activation were
observed in the GRK5KO mice [13]. Therefore, we specu-
lated that one reason for the absence of microgliosis in
these animals might be due to lack of inflammatory initi-
ators, such as fibrillar Aβ, or any of the downstream chem-
okines or anaphylatoxins.
In this study, we crossbred the GRK5KO mice with
TgAPPsw (Tg2576) mice. TgAPPsw mice overexpress
human  β-amyloid precursor protein (βAPP) carrying
Swedish double mutations, and have been shown to dis-
play fibrillar Aβ deposition and moderate levels of inflam-
mation [14-16]. Therefore, the resultant TgAPPsw mice
deficient in GRK5 should provide an ideal model to deter-
mine if our previous speculations are correct, and GRK5
deficiency plays a significant role in enhancing brain
inflammation in AD.
Methods
Animals
GRK5KO mice were generated by targeted deletion of
exons 7 and 8 of the GRK5 gene, encoding critical sub-ele-
ments I through III of the protein kinase catalytic domain,
as detailed previously [17]. Heterozygous GRK5KO mice
(C57/BL6 background) were bred with TgAPPsw
(Tg2576) mice (also with a C57/BL6 background) to pro-
duce wild type (WT, APPsw-/-/GRK5+/+, n = 6), GRK5KO
(APPsw-/-/GRK5+/-, n = 6), TgAPPsw (APPsw+/-/GRK5+/+, n
= 6), and the double (APPsw+/-/GRK5+/-, n = 6) mice for
this study. Due to known gender difference [18-20] [Li,
2008, BRB-submitted], only female mice (18-month old)
were used in this study. A tail DNA preparation was used
for genotyping as described below. All procedures for
using these animals were approved by the KCVAMC Insti-
tutional Animal Care and Use Committee.
Genotyping
Mouse-tail DNA was prepared as previously described
[13]. Genotyping was performed by polymerase chain
reaction (PCR) amplification of the tail genomic DNA
with five different primers together: two human APP-spe-
cific primers, 5'CGGAGGAGGATGACTCGGAT3' and
5'CAGCTGCTGTCTCTCGTTGG3', which amplify a 500
bp DNA fragment, were used to identify the presence of
the human APP transgene; three additional primers spe-
cific for WT murine GRK5 (425 bp) and the GRK5KO loci
(200 bp) (5'CAAGTGTGAGGTAGGGTACAGAAT3',
5'CTATCCATTCACCTCCATGCTCCC3', and
5'AACTCTGGTACAGACAGGATCTCT3') were used to
identify the presence of WT or the targeted murine GRK5
gene. The PCR used a 20 μl reaction volume containing
1.25 units of Flexi DNA polymerase (Promega, Madison,
WI), 200 μM dNTPs, 2 mM MgCl2, and 250 nM of each of
the APP preimers and 1 μM of each of the three GRK5
primers. The amplification protocol entailed 35 cycles ofJournal of Neuroinflammation 2008, 5:24 http://www.jneuroinflammation.com/content/5/1/24
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denaturation at 94°C for 15 s, annealing at 62°C for 15 s
and extension at 72°C for 15 s, and then followed by a 10-
min final extension at 72°C. The PCR products (10 μl)
were then analyzed and visualized on 1.5% agarose gels.
Fig. 1 shows an example of a typical genotyping result
including the four different genotypes used in this study.
Tissue preparations
All animals were anesthetized and perfused with cold
phosphate buffered saline (PBS), their brains removed,
and left hemispheres were post-fixed with 4% paraformal-
dehyde and processed for pathology. To minimize exper-
imental variations, multi-brain embedding and
sectioning techniques were adapted according to previ-
ously published procedures [13]. Briefly, twenty-four left
hemispheres (including six from each genotype) were
embedded into six blocks, with each block containing one
hemisphere from each of the WT, GRK5KO, APP and the
double mice, respectively. The multi-brain embedding
allows the subsequent sectioning and staining procedures
for all samples in a single block to be performed in a uni-
fied condition, which reduces variations that often occur
when each brain is manipulated separately. Frozen sec-
tions were taken at a thickness of 20 μm in the coronal
plane through the hemispheres. All sections were col-
lected sequentially into eight groups with 160 μm inter-
vals.
Immunofluorescent (IF) staining
IF staining was performed on the multi-brain sections as
previously described [13]. The only difference was the tar-
get antibody used: mouse monoclonal antibody (mAb) to
human Aβ (Alpha Diagnostics International, San Anto-
nio, TX; 1:600), rat mAb to CD45 (MCA1388, Clone: IBL-
3/16, Serotec, Raleigh, NC; 1:25), rat mAb to mouse
CD11b (Mac-1, Clone: M1/70.15, Serotec, Raleigh, NC;
1:25), mouse mAb to CD11b/c (Clone MRC OX-42, Sero-
tec, Raleigh, NC; 1:25), rabbit polyclonal antibody (pAb)
to human IL-1β (Santa Cruz Biotechnology, Santa Cruz,
CA; 1:25), mAb to glial fibrillary acidic protein (GFAP)
conjugated to Cy3 (Sigma, St. Louis, MO;1:200), or rabbit
pAb to IL-6 (Pierce Biotechnology, Rockford, IL; 1:100).
DAPI (Invitrogen Corporation, Carlsbad, CA) was used to
detect nuclei.
Image Analysis
For quantitative image analysis, serial coronal sections
taken from 1.70 to 3.16 mm posterior to the bregma were
examined for CD45+ microglia and GFAP+ astrocytes. Six
animals from each group were evaluated. For each animal,
antigens were detected in 5 parallel multi-brain sections
having a defined distance of 160 μm and showing both
the hippocampus and cortex. In each section, the hippoc-
ampus and the cortex were evaluated for the number of
stained cells, and integral staining density (sum of all
individual optical densities of each pixel in the area being
measured). Images were acquired as digitized tiff files to
retain maximal resolution using a Leica DMI 6000 B
microscope microscope at 100 × final magnification with
an attached digital camera system (Leica DFC 340 FX,
Heerbrugg, Germany). The digital images were then
routed into a Windows PC for quantitative analyses using
Genotypes and GRK5 expression in TgAPPsw mice with  reduced GRK5 Figure 1
Genotypes and GRK5 expression in TgAPPsw mice 
with reduced GRK5. Top panel, an example of the geno-
typing results for the WT (APPsw-/-/GRK5+/+), heterozygote 
GRK5KO (APPsw-/-/GRK5+/-), TgAPPsw (APPsw+/-/GRK5+/
+), and the double mice (APPsw+/-/GRK5+/-) using the 
ascribed five primers. 500 base pair (bp) band, human APPsw; 
425 bp band, WT GRK5; 200 bp band, inactivated GRK5. 
Bottom panels are representative Western blots for GRK5 
and β-actin (internal control for the amounts of sample 
loaded), respectively, as indicated.Journal of Neuroinflammation 2008, 5:24 http://www.jneuroinflammation.com/content/5/1/24
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Image-Pro Plus software, with the examiner blinded to
sample identifiers. To maintain consistency across ani-
mals, a rectangular box (0.42 × 0.26 mm) was centered
over the area of interest. Except for fewer sections used, all
other quantifying procedures were the same as stereologi-
cal quantification. The final results were shown as number
of immunopositive cells or immunoreactivity per mm2.
Western blot
At euthanasia, the cold PBS-perfused right hemispheres
were further dissected into anterior cortex, posterior cor-
tex, striatum, hippocampus, brainstem, and cerebellum.
Protein extract preparation, total protein content determi-
nation, western blotting, and semi-quantitative analyses
were performed as previously described [10,13]. Primary
Abs used were: rabbit pAb to GRK5 (Santa Cruz Biotech-
nology, Santa Cruz, CA; 1:200) and mAb to β-actin
(Sigma, St. Louis, MO; 1:1000).
Statistics
Data were expressed as the mean ± S.E.M, and analyzed by
ANOVA using Prism 4.3 (GraphPad Software, San Diego,
CA). Post-hoc comparisons of means were made using
Bonferroni's method with significance set at 0.05.
Results
In order to determine whether GRK5 deficiency has an
impact on brain inflammation in AD, we crossbred the
TgAPPsw mice with the GRK5KO mice and generated the
TgAPPsw mice deficient in GRK5. Only heterozygotes
were used in this study, which included four genotype
groups: WT control (APPsw-/-/GRK5+/+), GRK5KO hetero-
zygote control (APPsw-/-/GRK5+/-), TgAPPsw (APPsw+/-/
GRK5+/+) and the double (APPsw+/-/GRK5+/-) mice. As
shown in Fig. 1, inactivation of one copy of the GRK5
gene resulted in at least 50% down-regulation of the
GRK5 expression at the protein level in the heterozygote
GRK5KO and the double mice.
Evaluation of potential changes in brain inflammation
was performed in 18-month old female mice, due to the
known gender impact in these mice [18-20] [Li, 2008,
BRB-submitted]. Immunofluorescent staining with anti-
bodies against microglial and astrocyte markers was
employed to reveal changes in microgliosis and astroglio-
sis. Our initial examination with antibody against CD45,
a surface marker of microglia [15], revealed an increase of
microgliosis in both hippocampal (Fig. 2A–D) and corti-
cal (Fig. 2E–H) areas of the double mice as compared to
the TgAPPsw mice. Subsequent characterization of the
microgliosis showed that, consistent with previous find-
ings [15], CD45+ microglial cells were largely located sur-
rounding or near Aβ deposits (Fig. 3A–C). Staining with a
rat mAb to CD11b (Mac-1), another well-established
microglial and macrophage marker [15,21], revealed sim-
ilar changes of microglia in these animals (Fig. 3D–F). In
addition, a mouse mAb OX-42 to CD11b/c also decorated
the activated microglial cells in a way similar to anti-CD45
Increased CD45+ microglial cells in hippocampus and cortex  of the TgAPPsw mice with reduced GRK5 Figure 2
Increased CD45+ microglial cells in hippocampus and 
cortex of the TgAPPsw mice with reduced GRK5. 
Representative IF results with anti-CD45 staining (green) in 
hippocampus (A-D) and cortex (F-I) of WT (A &F), heter-
ozygote GRK5KO (B &G), TgAPPsw (C &H), and the dou-
ble mice (D &I), respectively. Scale bar in panel I is for panels 
A-D and F-I: 100 μm. Panels E &J, examples of high magnifi-
cation views of CD45+-microglial cells in hippocampus (E) 
and cortex (J) of the double mice that show details of acti-
vated microglial morphology. Scale bar in panel J is for panels 
E &J: 20 μm. Blue indicates reference DAPI staining of nuclei.Journal of Neuroinflammation 2008, 5:24 http://www.jneuroinflammation.com/content/5/1/24
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(Fig. 3G). However, at least in our experiments, OX-42
appeared to non-specifically stain the Aβ plaques, in addi-
tion to its positive staining for microglial cells. It has been
previously established that activated microglial cells, at
least at the early phase, produce IL-1β, an important
proinflammatory cytokine that participates in a self-sus-
tained vicious cycle to amplify the inflammatory neuronal
damage [2]. Our examination revealed that, although less
profound than CD45 immunoreactivity (IR), IL-1β-IR was
indeed found near or surrounding the Aβ plaques (Fig.
3H) and was colocalized with CD45+ microglial cells (Fig.
3I). Therefore, the microgliosis in the double mice dis-
played similar traits to that observed in other AD trans-
genic models, except for the exaggerated extent.
To better understand the extent of the exaggerated micro-
gliosis in these animals, we quantified CD45+ microglial
cells per mm2 in hippocampus and cortex. Our quantita-
tive image analysis (Fig. 4A &4B) showed that, as com-
pared to the WT mice, both the TgAPPsw and the double
mice displayed significantly more CD45+ microglial cells
in both of the examined brain regions (p < 0.001 for all);
when compared to the TgAPPsw mice, the double mice
had approximately double the number of CD45+ micro-
glial cells, in both hippocampus and cortex (P < 0.001). In
addition, the heterozygote GRK5KO mice did not show
any significant changes in the number of CD45+ micro-
glial cells, as compared to the WT, which is consistent with
our previous report for the negative finding of brain
inflammation in the GRK5KO mice [13]. When two-way
ANOVA was used to analyze interactions between the two
gene modifications (over-expression of human APPsw
and inactivation of one copy of the murine GRK5 gene), a
significance of p < 0.001 was revealed. Meanwhile, the
changes caused by both gene modifications in the double
mice were significantly higher than the sum of the
changes caused by APPsw over-expression in TgAPPsw
and by GRK5 gene inactivation in GRK5KO mice (p =
0.003 for hippocampus and p < 0.001 for cortex). These
results indicate that the two gene modifications synergis-
tically interact with each other, and both contribute the
microgliosis observed in the double mice.
In parallel to the microglial analysis, potential changes of
astrogliosis in these animals were also assessed using IF
staining with antibody to GFAP, an astrocyte-specific
intermediate filament protein. We found more hyper-
trophic astrocytes brightly stained with anti-GFAP in both
hippocampus and cortex from the double mice as com-
pared to the TgAPPsw mice, and both the double mice
and the TgAPPsw mice showed more hypertrophic astro-
cytes than the WT or heterozygous GRK5KO mice (Fig.
5A–H). Further characterization of the astrogliosis in the
double mice revealed that although some of the hyper-
trophic astrocytes located near Aβ plaques (Fig. 6A–C),
compared to the relation of microglia to Aβ plaques,
hypertrophic astrocytes were more widespread in the
entire brain region. In addition, at least some of the reac-
tive astrocytes were IL-6 positive (Fig. 6D–F). Quantitative
Colocalization of activated microglial cells with Aβ plaques  and IL-1β immunoreactivity in the TgAPPsw mice with  reduced GRK5 Figure 3
Colocalization of activated microglial cells with Aβ 
plaques and IL-1β immunoreactivity in the TgAPPsw 
mice with reduced GRK5. Panels A-C, IF staining of Aβ+ 
plaques (A, red) and surrounding CD45+ microglial cells (B, 
green), as well as their merged view (C) in the double mice. 
Scale bar: 50 μm for panels A-C. Panels D-F, IF staining of 
Aβ+ plaques (D, red) and surrounding CD11b+ microglial 
cells (E, green), as well as their merged view (F) in the dou-
ble mice. Scale bar: 50 μm for panels D-F. Panel G, an exam-
ple of merged view for CD45 (green) and CD11b/c (clone 
OX42, red) co-staining of the microglial cells. The image 
showed that, at least in this particular experimental para-
digm, the CD45 antibody stained more specifically for the 
microglial cell profiles; while the OX42 antibody, in addition 
to its positive staining of the microglial cells, also non-specifi-
cally decorated the plaques. Scale bar: 45 μm. Panel H, an 
example of merged view for Aβ+ plaques (red) and surround-
ing IL-1β immunoreactivity (green) in the double mice. Scale 
bar: 30 μm. Panel I, colocalization of CD45+ microglial cells 
(green) with IL-1β immunoreactivity (red) in the double 
mice. Scale bar: 30 μm. Blue indicates reference DAPI stain-
ing of nuclei.Journal of Neuroinflammation 2008, 5:24 http://www.jneuroinflammation.com/content/5/1/24
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image analysis (Fig. 7A &7B) indicated that both the
TgAPPsw and the double mice showed significantly more
GFAP+ astrocytes in the hippocampus and cortex (p <
0.001 for all) as compared to either the WT or the hetero-
zygous GRK5KO mice; furthermore, the double mice dis-
played greater numbers of astrocytes than that in the
TgAPPsw mice (p < 0.01 for hippocampus and p < 0.001
for cortex). Consistent with our previous report [13], the
number of GFAP+ astrocytes was not significantly different
between the heterozygous GRK5KO and the WT mice.
When two-way ANOVA was employed, significant inter-
actions (p < 0.05 for hippocampus, and p < 0.01 for cor-
tex) were revealed between the two gene modifications.
The comparisons of effects of the double gene modifica-
tions with the sum of the effects of the each single gene
modification alone revealed significant difference for the
cortex (p = 0.02) but not for the hippocampus (p = 0.10).
It is known that both resting and reactive astrocytes
express GFAP, but the latter usually expresses higher level
of GFAP, and therefore stain brighter. Because of this,
counting the number of GFAP+ astrocytes may not accu-
rately reflect the extent of the astrogliosis. Therefore, a
quantitative image analysis of GFAP-IR intensity was also
performed in parallel to the GFAP+ cell counting. The
results were similar to those from simple cell number
counting, except that the significance was more striking
(Fig. 7C &7D). The double gene modification effects were
significantly higher than the sum of the each single gene
alone for both hippocampus (p = 0.006) and cortex (p =
0.009). The interactions between the two gene modifica-
tions were also highly significant for both brain regions (p
= 0.002 for hippocampus, and p = 0.005 for cortex).
Therefore, these results suggest that Swedish mutated APP
gene over-expression and GRK5 deficiency synergistically
interact with each other to promote the astrogliosis
observed in the double mice.
Discussion
By analyzing the extent of gliosis in the brains of TgAPPsw
mice with normal or reduced GRK5 expression, we dem-
onstrated that the TgAPPsw mice with reduced GRK5 dis-
played significantly exaggerated microgliosis and
astrogliosis. Consistent with our previous report [13],
Quantification of CD45+ microglial cells in hippocampus and  cortex of the TgAPPsw mice with reduced GRK5 Figure 4
Quantification of CD45+ microglial cells in hippocam-
pus and cortex of the TgAPPsw mice with reduced 
GRK5. The numbers of CD45+ microglial cells in hippocam-
pus (A) and cortex (B) of WT, heterozygote GRK5KO, 
TgAPPsw, and the double mice were quantified as described 
in methods. Two way-ANOVAs revealed significant interac-
tions between APPsw and GRK5 gene modifications for both 
hippocampus and cortex (P < 0.001 for both regions). The 
results for Bonferroni post-hoc comparisons of the means 
were shown as indicated. **P < 0.001 vs WT or heterozy-
gote GRK5KO, ##P < 0.001 vs TgAPPsw mice.
Increased GFAP+ astrocytes in hippocampus and cortex of  the TgAPPsw mice with reduced GRK5 Figure 5
Increased GFAP+ astrocytes in hippocampus and cor-
tex of the TgAPPsw mice with reduced GRK5. Repre-
sentative IF results with anti-GFAP staining (green) in 
hippocampus (A-D) and cortex (E-H) of WT (A &E), het-
erozygote GRK5KO (B &F), TgAPPsw (C &G), and the dou-
ble mice (D &H), respectively. Blue indicates reference DAPI 
staining of nuclei. Scale bar: 100 μm.Journal of Neuroinflammation 2008, 5:24 http://www.jneuroinflammation.com/content/5/1/24
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GRK5 deficiency alone does not lead to any significant
inflammatory changes in either the heterozygote or
homozygote GRK5KO mice. However, when an inflam-
mation is present, as evoked by overexpression of the
Swedish mutated APP gene, the GRK5 deficiency synergis-
tically interacts with the active inflammatory processes
and leads to amplified inflammatory responses. Such phe-
nomena are consistent with the manner of GRK action, as
GRKs are not thought to induce signals directly, but
rather, they primarily modify the activity of activated
GPCRs by uncoupling the receptor from G-protein, and
initialing receptor internalization [11,12]. In the
GRK5KO mice, the reason why we did not observe a sig-
nificant inflammation is likely because there was no an
active inflammatory signaling for the GRK5 to act on. In
the double mice, however, when Swedish mutated APP
was overexpressed, the accumulation of fibrillar Aβ initi-
ated a complex of active inflammatory processes, which
provided an opportunity to reveal impact of GRK5 defi-
ciency. As demonstrated in this study, inactivation of one
copy of the native GRK5 gene led to approximately dou-
bled extent of microgliosis and significantly exaggerated
astrogliosis. Therefore, these in vivo results strongly sup-
port the model that GRK5 deficiency indeed plays a signif-
icant role in amplifying the brain inflammatory responses
in AD, as we previously speculated.
Since the primary role of GRKs is to desensitize GPCRs
and dampen the activated GPCRs signaling, deficiency of
GRK5 may lead to hyperactivity of those GPCRs that are
specifically regulated by GRK5. As previously demon-
strated, the fibrillar Aβ can initiate a complicated inflam-
matory process, which may include increased levels of
proinflammatory cytokines, chemokines, and activated
complement components [1-7]. It is known that receptors
for all chemokines and the anaphylatoxin C3a and C5a
Colocalization of reactive astrocytes with Aβ plaques and IL- 6 immunoreactivity in the TgAPPsw mice with reduced  GRK5 Figure 6
Colocalization of reactive astrocytes with Aβ plaques 
and IL-6 immunoreactivity in the TgAPPsw mice 
with reduced GRK5. Panels A-C, IF staining of Aβ+ plaques 
(A, red) and nearby GFAP+ reactive astrocytes (B, green), as 
well as their merged view (C) in the double mice. Scale bar: 
50 μm for panels A-C. Panels D-F, IF staining of GFAP+ 
astrocytes (D, red) and colocalized IL-6-IR (E, green), as well 
as their merged view (F) in the double mice. Scale bar: 20 μm 
for panels D-F. Blue indicates reference DAPI staining of 
nuclei.
Quantification of GFAP+ astrocytes in hippocampus and cor- tex of the TgAPPsw mice with reduced GRK5 Figure 7
Quantification of GFAP+ astrocytes in hippocampus 
and cortex of the TgAPPsw mice with reduced 
GRK5. Both the numbers of GFAP+ astrocytes (A &B) and 
the intensity of GFAP-IR (C &D) in hippocampus (A &C) and 
cortex (B &D) of WT, heterozygote GRK5KO, TgAPPsw, 
and the double mice were quantified as described in meth-
ods. Two way-ANOVAs revealed significant interactions 
between APPsw and GRK5 gene modifications with the 
interaction factors of p < 0.05 for panel A, and p < 0.01 for 
panels B, C, and D. The results for Bonferroni post-hoc 
comparisons of the means were shown as indicated. **P < 
0.001 vs WT or GRK5KO; #P < 0.01, ##P < 0.001 vs 
TgAPPsw mice.Journal of Neuroinflammation 2008, 5:24 http://www.jneuroinflammation.com/content/5/1/24
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are GPCRs [6,8,9]. In fact, even fibrillar Aβ itself has been
shown to activate GPCRs, such as macrophage scavenger
receptor, or formyl chemotactic receptor 2 (FPR2 or FPRL-
1) [22-24]. Therefore, theoretically, all these GPCRs could
be potential substrates for GRK5. On the other hand,
however, the substrate spectrums for different GRK mem-
bers may overlap, and the lost function due to deficiency
of one GRK member may be largely compensated by other
GRK members [11,12]. Only when the lost function can-
not be fully compensated, a phenotype relevant to the
specific GPCR signaling can then be revealed. For exam-
ple, GRK2, GRK5, and GRK6 KO mice have been shown
to display selectively impaired desensitization of adrener-
gic, muscarinic and dopaminergic receptors, respectively
[17,25,26]. Unfortunately, to the best of our knowledge,
information regarding the specific regulation of GRK5 on
most, if not all, of the GPCRs involved in the fibrillar Aβ
initiated inflammatory processes, particularly the in vivo
data, is unavailable. Therefore, further investigations are
warranted to understand the detailed molecular mecha-
nisms by which the GRK5 deficiency exaggerates the brain
inflammation in the TgAPPsw mice.
The main purpose of this study was to determine whether
or not GRK5 deficiency in vivo contributes to exaggerate
brain inflammation, and the results confirmed the posi-
tive role of GRK5 deficiency in the TgAPPsw mice. In the
meantime, the fact that the double mice displayed signif-
icantly stronger inflammatory changes than those in the
TgAPPsw mice makes the double mice a distinct model
from the original TgAPPsw mice. It has been suggested
that inflammatory responses in currently available APP
transgenic mouse models, including the TgAPPsw mice,
are not as strong as those in human AD patients [16].
Therefore, at least in resembling the strength of the
inflammatory responses in AD, the TgAPPsw mice with
reduced GRK5 may be a better model than the single
TgAPPsw mice, and should serve as an additional AD ani-
mal model for relevant studies.
Conclusion
This study has demonstrated that GRK5 deficiency in vivo
significantly exaggerates the microgliosis and astrogliosis
in the presence of an inflammatory initiator, the excess
fibrillar Aβ and the subsequent active brain inflammatory
reactions in the TgAPPsw mice. In the absence of an active
inflammatory response, however, the effects of the GRK5
deficiency on inflammation in vivo remain silent. These
findings, along with our previous findings for the role of
GRK5 deficiency in promoting axonal defects and synap-
tic degeneration [13] [Li, 2008, BRB-submitted], strongly
support that the hypothesis that GRK5 deficiency plays a
significant role in AD pathogenesis. In addition, the
TgAPPsw mouse combined with deficient GRK5 is a better
model than the single TgAPPsw mouse, due to a stronger
resemblance to the strength of the inflammatory
responses in AD.
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